PanGen Biotech Balance Sheet Health
Financial Health criteria checks 6/6
PanGen Biotech has a total shareholder equity of ₩18.0B and total debt of ₩2.3B, which brings its debt-to-equity ratio to 12.6%. Its total assets and total liabilities are ₩25.4B and ₩7.4B respectively.
Key information
12.6%
Debt to equity ratio
₩2.28b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩5.99b |
| Equity | ₩18.02b |
| Total liabilities | ₩7.35b |
| Total assets | ₩25.37b |
Financial Position Analysis
Short Term Liabilities: A222110's short term assets (₩15.2B) exceed its short term liabilities (₩4.6B).
Long Term Liabilities: A222110's short term assets (₩15.2B) exceed its long term liabilities (₩2.7B).
Debt to Equity History and Analysis
Debt Level: A222110 has more cash than its total debt.
Reducing Debt: A222110's debt to equity ratio has reduced from 77.5% to 12.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable A222110 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: A222110 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 13.8% per year.